Chk1-Targeted Hesperidin Liposomes for Breast Cancer Therapy: An Integrated In Silico, In Vitro , and In Vivo Evaluation
ACS Applied Bio Materials · 21.05.2026
DOI: 10.1021/acsabm.6c00143 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Bio Materials, online erschienen am 21.05.2026. Verfasst von Nandini Markuli Sadashivappa und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, M.S. Ramaiah University of Applied Sciences, Bangalore, Karnataka 560054, India. Hauptthemen laut MEDLINE: Hesperidin, Breast Neoplasms, Checkpoint Kinase 1, Antineoplastic Agents. Die Arbeit nennt 66 Literaturangaben.
Abstract (Originalsprache)
Checkpoint 1 kinase (Chk1) regulates the cell cycle and facilitates DNA repair processes, which are essential for maintaining genomic integrity. In breast cancer, Chk1 is frequently overexpressed, enabling tumor cells to endure DNA damage. By blocking Chk1, a crucial regulator of the development and spread of malignancies, the current study investigates the potential of natural products to identify different treatment approaches for breast cancer. Based on the molecular docking, absorption, distribution, metabolism, excretion, and toxicity profiling and molecular dynamics simulations, hesperidin (NP621) interacted with important Chk1 residues, demonstrated good stability over 800 ns, and had a favorable binding energy of −9.6 kcal/mol. Liposomal encapsulation was employed to overcome hesperidin’s low solubility and poor bioavailability, thereby enhancing its stability and therapeutic potential in cancer treatment. The liposomal formulations were characterized by Fourier transform infrared, X-ray diffraction, and transmission electron microscopy (FTIR, XRD, particle size analysis, and TEM), confirming successful liposomal binding. Hesperidin encapsulated liposomes (HSP-LLPs) displayed remarkable cytotoxicity against the MCF-7 breast cancer cells (IC 50 of 13.52 μg/mL) and significantly inhibited angiogenesis in the chorioallantoic membrane assay. HSP-LLPs reduced tumor burden, restored hematological and biochemical parameters, and improved tissue architecture in a 7,12-dimethylbenz[α]anthracene-induced rat model of breast cancer. These findings demonstrate that Chk1-targeted hesperidin liposomes represent a promising translational nanomedicine approach for breast cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, M.S. Ramaiah University of Applied Sciences, Bangalore, Karnataka 560054, India.
- Department of Pharmacology, Faculty of Pharmacy, M.S. Ramaiah University of Applied Sciences, Bangalore, Karnataka 560054, India.
- Laboratory of Functional Molecules and Materials, School of Physics and Optoelectronic Engineering, Shandong University of Technology, Xincun West Road 266, Zibo 255000, China.
- UConn School of Pharmacy and Pharmaceutical Sciences, Storrs, Connecticut 06269, United States.
- Department of Biotechnology, Alliance University, Anekal, Bengaluru, Karnataka 562106, India.
- School of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University (A Central University), Vidya Vihar, Raebareli Road, Lucknow 226025, India.
ORCID-Profile: Prabu Kumar Seetharaman, Selvaraj Kunjiappan, Paruvathanahalli Siddalingam Rajinikanth, Parasuraman Pavadai
Zitieren
APA
Markuli Sadashivappa, N., Hosur Dinesh, B. G., Olakkengil Shajan, S. R., Bandral, S. K., Ganjipete, S., Hanumanthappa, D., Walikar, S. K., Seetharaman, P. K., Ramar, M., Kunjiappan, S., Rajinikanth, P. S., Ammunje, D. N., & Pavadai, P. (2026). Chk1-Targeted Hesperidin Liposomes for Breast Cancer Therapy: An Integrated In Silico, In Vitro , and In Vivo Evaluation. ACS Applied Bio Materials. https://doi.org/10.1021/acsabm.6c00143
Vancouver
Markuli Sadashivappa N, Hosur Dinesh BG, Olakkengil Shajan SR, Bandral SK, Ganjipete S, Hanumanthappa D, et al. Chk1-Targeted Hesperidin Liposomes for Breast Cancer Therapy: An Integrated In Silico, In Vitro , and In Vivo Evaluation. ACS Applied Bio Materials. 2026. doi:10.1021/acsabm.6c00143
BibTeX
@article{MarkuliSadashivappa2026,
author = {Markuli Sadashivappa, Nandini and Hosur Dinesh, Basavana Gowda and Olakkengil Shajan, Sandra Ross and Bandral, Sunil Kumar and Ganjipete, Srinivas and Hanumanthappa, Devaraj and Walikar, Shivaraj Kumar and Seetharaman, Prabu Kumar and Ramar, Mohankumar and Kunjiappan, Selvaraj and Rajinikanth, Paruvathanahalli Siddalingam and Ammunje, Damodar Nayak and Pavadai, Parasuraman},
title = {Chk1-Targeted Hesperidin Liposomes for Breast Cancer Therapy: An Integrated In Silico, In Vitro , and In Vivo Evaluation},
journal = {ACS Applied Bio Materials},
year = {2026},
doi = {10.1021/acsabm.6c00143}
}
EUVIMED